A Phase 1 Study of HLX20 a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    Sep 22, 2021
  • participants needed
    30
  • sponsor
    Shanghai Henlius Biotech
Updated on 22 January 2021

Summary

This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy.

Description

Tumor microenvironment plays an important role in the interaction of immune cells with cancer . The identification of programmed cell death receptor 1 (PD-1) and programmed death ligand-1 (PD-L1) have provided the scientific rationale and supports the clinical development of agents targeting this pathway. Currently, PD-1 and PD-L1 inhibitory pathway blockade has demonstrated impressive activity against a spectrum of multiple tumor types, including Hodgkin's lymphoma, melanoma, bladder cancer, lung cancer, renal cell carcinoma.

HLX20 is a novel anti-PD-L1 monoclonal antibody. In the nonclinical pharmacology studies, HLX20 has demonstrated anti-tumor activities in xenogenic animal models comparable to currently available anti-PD-L1 monoclonal antibodies. HLX20 binds to PD-1 and PD-L1 inhibitory pathway and human PD-L1 at high affinity, and mouse PD-L1 at much lower affinity. HLX20 does not cause hemolysis to human red blood cells and has no local irritation to human tissues. (The results of pharmacokinetic (PK)/toxicokinetic studies in cynomolgus studies have been described in detail in the Investigator's Brochure.)The no-observable adverse effect level (NOAEL) is set at 100 mg/kg every 2 weeks for 13 weeks in cynomolgus studies.

Based on these results, the initial dose 1 mg/kg every 2 weeks was chosen for this study .This dose level is approximately 30-fold lower than the human equivalent dose of NOAEL from preclinical toxicology studies. An adaptive Bayesian dose-finding design will be used to identify the MTD (maximum tolerated dose). The target toxicity rate for the MTD is set at 0.3 and the maximum sample size is 30.The safety profiles at different dose levels, PK parameters, biomarkers, pharmacodynamic markers, immunogenicity as well as the preliminary efficacy of the drug, will also be investigated in this study.

Details
Condition Advanced Solid Tumors
Treatment HLX20
Clinical Study IdentifierNCT03588650
SponsorShanghai Henlius Biotech
Last Modified on22 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Advanced Solid Tumors?
Do you have any of these conditions: Do you have Advanced Solid Tumors??
Males or females of 18 years of age or older (or per local regulations)
Have histologically-proven measurable, or evaluable advanced (systemically or locally progressive), or metastatic solid tumors or the locally advanced disease is not amenable to local therapy, who have failed, or are intolerant to standard therapy or for whom no standard therapy is available. (For patients with hepatocellular carcinoma, the diagnosis needs to be supported by dynamic computed tomography [CT]/magnetic resonance imaging, if pathological confirmation is not attainable)
Eastern Cooperative Oncology Group (ECOG) performance status of 2 at the time of study entry
Able to comprehend and provide informed consent
A life expectancy longer than 3 months in the opinion of the Investigator
Adequate hematologic functions, as defined by: absolute neutrophil counts
mm3; a hemoglobin level 10 g/dL; a platelet count 100,000/mm3
\. Adequate hepatic function defined by: a total bilirubin level 1.5 of upper
limit of normal (ULN); aspartate transaminase and alanine transaminase levels
5 ULN or 5 ULN in known hepatic metastases or with primary hepatocellular
carcinoma
\. Adequate renal function, as defined by the creatinine clearance 50
mL/minute (as calculated by the Cockcroft-Gault formula)
\. Adequate cardiac function defined as left ventricular ejection fraction
% by cardiac ultrasound or multigated acquisition (MUGA) scan. A recent MUGA
scan is acceptable if performed within 8 weeks of the first infusion of IP
\. Females of child-bearing potential must have a negative pregnancy test
upon entry into this study and must be willing to use highly effective birth
control upon enrollment, during the Treatment Phase and for 180 days following
the last dose of study drug. A female is considered of child-bearing potential
following menarche and until becoming postmenopausal (no menstrual period for
a minimum of 12 months) unless permanently sterile (undergone a hysterectomy
bilateral salpingectomy, or bilateral oophorectomy)
\. If male, must be surgically sterile or willing to use highly effective
birth control upon enrollment, during the Treatment Phase, and for 180 days
following the last dose of study drug
\. History of prior major surgery, prior cytotoxic chemotherapy, or prior
therapy with investigational agents, medical device, or local radiotherapy
should be at least 28 days prior to Screening and at least 42 days from the
last infusion of immune check point inhibitors (including anti-programmed cell
death receptor-1 [PD-1] or anti-PD-L1) before the first infusion of IP
\. Child-Pugh score of A (patients with hepatocellular carcinoma only)
\. Able to be followed up as required by the study protocol

Exclusion Criteria

Persistent Grade 2 toxicities from prior therapies, with the exception of alopecia of any grade, Grade 2 peripheral neuropathy, and laboratory values listed per the inclusion criteria
Concurrent unstable or uncontrolled medical conditions, including
Active systemic infections
Poorly controlled hypertension (systolic blood pressure 160 mmHg or diastolic blood pressure 100 mmHg), or poor compliance with antihypertensive agents
Clinically significant arrhythmia, unstable angina pectoris, congestive heart failure (Class III or IV of New York Heart Association) or acute myocardial infarction within 6 months
Uncontrolled diabetes or poor compliance with hypoglycemic agents
The presence of chronically unhealed wound or ulcers
Other chronic diseases, which, in the opinion of the Investigator, could compromise safety of the patient or the integrity of the study
Newly-diagnosed or symptomatic brain metastases (patients with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and not be taking steroids for brain edema). Anticonvulsants are allowed. Patients with history of leptomeningeal disease will be excluded
Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for 3 years are allowed to participate)
Females who are pregnant, lactating, or intend to become pregnant during their participation in this study
Known history of human immunodeficiency virus infection
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis with the exception of diverticulosis, celiac disease, irritable bowel disease, Wegner syndrome) within the past 2 years. Patients with well controlled vitiligo, alopecia, and Grave's disease, hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement, or psoriasis not requiring systemic treatment (within the past 3 years), or patients with controlled Type 1 diabetes mellitus who are on a stable insulin regimen are not excluded
Current or prior use of immunosuppressive medication within 14 days before the first dose. The following are exceptions to this criterion
Intranasal, inhaled, topical steroids or local steroid injections (eg, intra-articular injection), OR
systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent, OR
steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
History of primary immunodeficiency or allogeneic transplantation
Active hepatitis B (HBsAg reactive). Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test followed by a positive HCV RNA test at Screening
History of interstitial lung disease
Receipt of live attenuated vaccines within 30 days prior to the first dose of IP. Patients, if enrolled, should not receive live or live attenuated vaccines during the study and for 30 days after the last dose of IP
The patient is the Investigator, sub-investigator or anyone directly involved in the conduct of the study
History or current evidence of any condition or disease that could confound the results of the study or, in the opinion of Investigator, is not in the best interest of the patient to participate
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note